AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (AARD) to Filing of Securities Fraud Class Action

Hagens Berman notified Aardvark Therapeutics investors of a pending securities class action covering shares purchased in or traceable to the February 13, 2025 IPO and purchases through May 14, 2026. The notice signals potential IPO-related disclosure or securities-law claims, creating a legal overhang for NASDAQ:AARD, though no alleged damages, case merits, or financial impact were disclosed.

Analysis

This is not a fundamental catalyst by itself: plaintiff-firm solicitation activity has low information content absent a filed complaint, lead-plaintiff appointment, dismissal ruling, or disclosure of damages theory. For AARD, the relevant transmission channel is incremental legal expense, management distraction, and a higher perceived probability that IPO-period disclosures face scrutiny; none is likely to alter near-term operating value unless the case survives a motion to dismiss or uncovers a material clinical, regulatory, or commercialization omission.

The more consequential market effect is liquidity-related. Small-cap biotech IPOs can experience persistent multiple pressure when litigation adds another reason for long-only holders to avoid averaging down, while borrow availability and short interest can make a directional short costly and unstable. Over the next 1-3 months, monitor the actual complaint, cash balance/runway, insider sales, and any change to trial, regulatory, or commercial guidance; a dismissal, immaterial reserve, or reaffirmed operational milestones would falsify the litigation-overhang thesis. Over 6-18 months, clinical execution and financing needs should dominate this headline entirely.

Key Decisions for Investors

• No new directional position solely on this notice; treat it as an alert rather than a trade until the complaint and alleged misstatement are publicly available.
• For existing AARD longs, reduce position sizing or hedge exposure ahead of the next earnings/clinical update if cash runway is below 12-18 months; litigation can compound dilution risk when financing is required. Reassess if management reaffirms milestones and the filing identifies no operationally material omission.
• Do not initiate a naked AARD short on the announcement: expected legal timing is long, fundamental damages are unquantified, and low-float biotech borrow/short-squeeze risk can dominate. Consider a defined-risk put structure only after confirming liquid options, borrow conditions, and a concrete adverse catalyst.
• Set a catalyst alert for lead-plaintiff deadline, complaint filing, motion-to-dismiss outcome, and any revision to clinical or regulatory guidance; a guidance cut or financing announcement would make the overhang investable, while dismissal or unchanged execution would argue against maintaining a hedge.